Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24168945 | 0.81 | KEAP1 (0.57) | CYP19A1TLR8KEAP1KMT2A | |
| SCHEMBL6431328 | 0.80 | KMT2A (0.55) | CYP19A1TLR8KMT2A | |
| SCHEMBL26215154 | 0.78 | LMNA (0.45) | CYP19A1KMT2A | |
| SCHEMBL11679229 | 0.76 | CYP19A1 (0.49) | CYP19A1TLR8KEAP1KMT2A | |
| SCHEMBL28782368 | 0.76 | KEAP1 (0.59) | CYP19A1TLR8KEAP1KMT2A | |
| SCHEMBL29933067 | 0.75 | CYP19A1 (0.39) | CYP19A1TLR8MGAT2 | |
| SCHEMBL28903876 | 0.74 | CYP19A1 (0.47) | CYP19A1TLR8KEAP1KMT2A | |
| SCHEMBL27753624 | 0.74 | CYP19A1 (0.47) | CYP19A1TLR8KEAP1KMT2A | |
| SCHEMBL27753622 | 0.73 | APOBEC3G (0.49) | CYP19A1KMT2A | |
| SCHEMBL24168406 | 0.72 | THRA (0.52) | CYP19A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | CYP19A1 4193/4885TLR8 4806/4885KEAP1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.